Experienced in Apoplexy

Dr. Gary Schwartz

Cardiology
Cardiology Consultants Of Philadelphia PC
1703 S Broad St Ste 300, 
Philadelphia,, PA 
Clinical Trials:Currently Recruiting for 1 Trial
Experienced in Apoplexy
Cardiology Consultants Of Philadelphia PC
1703 S Broad St Ste 300, 
Philadelphia,, PA 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Gary Schwartz is a Cardiologist in Philadelphia,, Pennsylvania. Dr. Schwartz is rated as an Experienced provider by MediFind in the treatment of Apoplexy. His top areas of expertise are Endocarditis, Hypertension, Glucocorticoid-Remediable Aldosteronism, Heart Failure, and Hormone Replacement Therapy (HRT).

His clinical research consists of co-authoring 17 peer reviewed articles and participating in 15 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Cardiology
Licenses
Internal Medicine in PA
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Highmark
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO

Locations

Cardiology Consultants of Philadelphia PC
1703 S Broad St Ste 300, Philadelphia,, PA 19148

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

14 Clinical Trials

A Phase 1 Study of Ruxolitinib, Steroids and Lenalidomide for Relapsed/Refractory Multiple Myeloma (RRMM) Patients
A Phase 1 Study of Ruxolitinib, Steroids and Lenalidomide for Relapsed/Refractory Multiple Myeloma (RRMM) Patients
Enrollment Status: Recruiting
Publish Date: November 01, 2023
Intervention Type: Drug
Study Drugs: Ruxolitinib Oral Tablet [Jakafi], Lenalidomide, Methylprednisolone
Study Phase: Phase 1
Genomically-Guided Treatment Trial in Brain Metastases
Genomically-Guided Treatment Trial in Brain Metastases
Enrollment Status: Suspended
Publish Date: December 12, 2025
Intervention Type: Drug
Study Drugs: Abemaciclib, Paxalisib, Entrectinib
Study Phase: Phase 2
NCI COVID-19 in Cancer Patients Study (NCCAPS): A Longitudinal Natural History Study
NCI COVID-19 in Cancer Patients Study (NCCAPS): A Longitudinal Natural History Study
Enrollment Status: Active_not_recruiting
Publish Date: November 17, 2025
Intervention Type: Other, Procedure
The CompassHER2 Trials (Comprehensive Use of Pathologic Response Assessment to Optimize Therapy in HER2-Positive Breast Cancer) CompassHER2 Residual Disease (RD), a Double-Blinded, Phase III Randomized Trial of T-DM1 Compared With T-DM1 and Tucatinib
The CompassHER2 Trials (Comprehensive Use of Pathologic Response Assessment to Optimize Therapy in HER2-Positive Breast Cancer) CompassHER2 Residual Disease (RD), a Double-Blinded, Phase III Randomized Trial of T-DM1 Compared With T-DM1 and Tucatinib
Enrollment Status: Active_not_recruiting
Publish Date: October 29, 2025
Intervention Type: Other, Biological, Drug
Study Drugs: Trastuzumab Emtansine, Tucatinib
Study Phase: Phase 3
eMonarcHER: A Randomized, Double Blind, Placebo-Controlled Phase 3 Study of Abemaciclib Plus Standard Adjuvant Endocrine Therapy in Participants With High-Risk, Node-Positive, HR+, HER2+ Early Breast Cancer Who Have Completed Adjuvant HER2-Targeted Therapy
eMonarcHER: A Randomized, Double Blind, Placebo-Controlled Phase 3 Study of Abemaciclib Plus Standard Adjuvant Endocrine Therapy in Participants With High-Risk, Node-Positive, HR+, HER2+ Early Breast Cancer Who Have Completed Adjuvant HER2-Targeted Therapy
Enrollment Status: Terminated
Publish Date: July 15, 2025
Intervention Type: Drug
Study Drugs: Abemaciclib, Standard Adjuvant Endocrine Therapy
Study Phase: Phase 3
A Randomized, Open Label, Phase III Trial to Evaluate the Efficacy and Safety of Palbociclib + Anti-HER2 Therapy + Endocrine Therapy vs. Anti-HER2 Therapy + Endocrine Therapy After Induction Treatment for Hormone Receptor Positive (HR+)/HER2-Positive Metastatic Breast Cancer
A Randomized, Open Label, Phase III Trial to Evaluate the Efficacy and Safety of Palbociclib + Anti-HER2 Therapy + Endocrine Therapy vs. Anti-HER2 Therapy + Endocrine Therapy After Induction Treatment for Hormone Receptor Positive (HR+)/HER2-Positive Metastatic Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: June 11, 2025
Intervention Type: Drug
Study Drugs: Palbociclib, Trastuzumab, Pertuzumab, Letrozole, Anastrozole, Exemestane, Fulvestrant
Study Phase: Phase 3
Phase II Randomized Placebo-Controlled Trial of Cisplatin With or Without ABT-888 (Veliparib) in Metastatic Triple-Negative Breast Cancer and/or BRCA Mutation-Associated Breast Cancer, With or Without Brain Metastases
Phase II Randomized Placebo-Controlled Trial of Cisplatin With or Without ABT-888 (Veliparib) in Metastatic Triple-Negative Breast Cancer and/or BRCA Mutation-Associated Breast Cancer, With or Without Brain Metastases
Enrollment Status: Completed
Publish Date: May 16, 2025
Intervention Type: Other, Drug
Study Drugs: Cisplatin, Veliparib
Study Phase: Phase 2
Alternate Approaches for Clinical Stage II or III Estrogen Receptor Positive Breast Cancer Neoadjuvant Treatment (ALTERNATE) in Postmenopausal Women: a Phase III Study
Alternate Approaches for Clinical Stage II or III Estrogen Receptor Positive Breast Cancer Neoadjuvant Treatment (ALTERNATE) in Postmenopausal Women: a Phase III Study
Enrollment Status: Active_not_recruiting
Publish Date: January 10, 2025
Intervention Type: Drug
Study Drugs: Fulvestrant, Anastrozole
Study Phase: Phase 3
Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients With High-Risk, Hormone Receptor-Positive and HER2/Neu Negative Breast Cancer
Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients With High-Risk, Hormone Receptor-Positive and HER2/Neu Negative Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: December 27, 2024
Intervention Type: Drug, Other
Study Drugs: Anastrozole, Everolimus, Exemestane, Goserelin Acetate, Letrozole, Leuprolide Acetate, Tamoxifen Citrate
Study Phase: Phase 3
A Randomized, Double-Blind, Phase III Trial of Taxane/Trastuzumab/Pertuzumab With Atezolizumab or Placebo in First-Line HER2-Positive Metastatic Breast Cancer
A Randomized, Double-Blind, Phase III Trial of Taxane/Trastuzumab/Pertuzumab With Atezolizumab or Placebo in First-Line HER2-Positive Metastatic Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: September 26, 2024
Intervention Type: Other, Procedure, Biological, Drug
Study Drugs: Atezolizumab, Paclitaxel, Pertuzumab, Trastuzumab
Study Phase: Phase 3
Phase II Pre-emptive OsciLLation of ER activitY Levels Through Alternation of Estradiol/Anti-estrogen Therapies Prior to Disease Progression in ER+/HER2- Metastatic or Advanced Breast Cancer
Phase II Pre-emptive OsciLLation of ER activitY Levels Through Alternation of Estradiol/Anti-estrogen Therapies Prior to Disease Progression in ER+/HER2- Metastatic or Advanced Breast Cancer
Enrollment Status: Completed
Publish Date: July 17, 2024
Intervention Type: Drug
Study Drugs: 17B-estradiol, Letrozole, Anastrozole, Exemestane
Study Phase: Phase 2
Phase 2 Randomized, Double-Blinded, Controlled Study of Tucatinib vs Placebo in Combination With Capecitabine and Trastuzumab in Patients With Pretreated Unresectable Locally Advanced or Metastatic HER2+ Breast Carcinoma
Phase 2 Randomized, Double-Blinded, Controlled Study of Tucatinib vs Placebo in Combination With Capecitabine and Trastuzumab in Patients With Pretreated Unresectable Locally Advanced or Metastatic HER2+ Breast Carcinoma
Enrollment Status: Completed
Publish Date: August 14, 2023
Intervention Type: Drug
Study Drugs: tucatinib, capecitabine, trastuzumab
Study Phase: Phase 2
Phase I Study of the Combination of MLN9708 and Fulvestrant in Patients With Advanced Estrogen Receptor Positive Breast Cancer
Phase I Study of the Combination of MLN9708 and Fulvestrant in Patients With Advanced Estrogen Receptor Positive Breast Cancer
Enrollment Status: Terminated
Publish Date: April 29, 2019
Intervention Type: Drug
Study Phase: Phase 1
Presurgical Treatment With Letrozole in Patients With Early-stage Breast Cancer.
Presurgical Treatment With Letrozole in Patients With Early-stage Breast Cancer.
Enrollment Status: Completed
Publish Date: January 17, 2019
Intervention Type: Drug
Study Phase: Not Applicable
View 13 Less Clinical Trials

17 Total Publications

Near-Infrared Spectral Tomography for Predicting Residual Cancer Burden during Early-Stage Neoadjuvant Chemotherapy for Breast Cancer.
Near-Infrared Spectral Tomography for Predicting Residual Cancer Burden during Early-Stage Neoadjuvant Chemotherapy for Breast Cancer.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: May 28, 2023
Similar Doctors
Bruce D. Klugherz
Distinguished in Apoplexy
Dr. Bruce D. Klugherz
Thoracic Surgery | Cardiology
Distinguished in Apoplexy
Dr. Bruce D. Klugherz
Thoracic Surgery | Cardiology

AMS Cardiology - Horsham

118 Welsh Road, 
Horsham, PA 
 (12.2 miles away)
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Bruce Klugherz is a Cardiologist and a Thoracic Surgeon in Horsham, Pennsylvania. Dr. Klugherz is rated as a Distinguished provider by MediFind in the treatment of Apoplexy. His top areas of expertise are Heart Attack, Apoplexy, Aortic Valve Stenosis, Transcatheter Aortic Valve Replacement (TAVR), and Aortic Valve Replacement. Dr. Klugherz is currently accepting new patients.

Zahi Rafeq
Distinguished in Apoplexy
Dr. Zahi Rafeq
Cardiology | Interventional Cardiology
Distinguished in Apoplexy
Dr. Zahi Rafeq
Cardiology | Interventional Cardiology
210 West Atlantic Avenue, 
Haddon Heights, NJ 
 (24.9 miles away)
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Zahi Rafeq is a Cardiologist and an Interventional Cardiologist in Haddon Heights, New Jersey. Dr. Rafeq is rated as a Distinguished provider by MediFind in the treatment of Apoplexy. His top areas of expertise are Heart Attack, Apoplexy, Angina, Heart Bypass Surgery, and Coronary Artery Bypass Graft (CABG). Dr. Rafeq is currently accepting new patients.

Daniel Tarditi
Distinguished in Apoplexy
Dr. Daniel Tarditi
Cardiology
Distinguished in Apoplexy
Dr. Daniel Tarditi
Cardiology
210 West Atlantic Avenue, 
Haddon Heights, NJ 
 (24.9 miles away)
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Daniel Tarditi is a Cardiologist in Haddon Heights, New Jersey. Dr. Tarditi is rated as a Distinguished provider by MediFind in the treatment of Apoplexy. His top areas of expertise are Hypertensive Heart Disease, Pediatric Myocarditis, Necrosis, Pacemaker Implantation, and Cardiac Ablation. Dr. Tarditi is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Schwartz's expertise for a condition
ConditionClose
        View All 15 Experienced Conditions
        Want to save this doctor for later?
        Sign Up
        Is this your doctor?
        Find A Second Opinion
        Not sure about your diagnosis?
        Check Your Symptoms
         
         
         
         
        Learn about our expert tiers
        Learn More
        Are you the provider on this profile?
        Claim Profile